Histone Deacetylase Inhibitors and Rational Combination Therapies

Advances in Cancer Research

Volumn 116, Issue , 2012, Pages 199-237

  Grant, Steven ^a   Dai, Yun ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Chromatin; Histone deacetylase inhibitors

Indexed keywords

APICIDIN; BELINOSTAT; BIM PROTEIN; BUTYRIC ACID; CHAPERONE; COREPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE 1; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ENTINOSTAT; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; ROMIDEPSIN; SURVIVIN; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BURKITT LYMPHOMA; CELL SURVIVAL; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG ACTIVITY; EPIGENETICS; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; LYMPHOMA CELL; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; UPREGULATION;

EID: 84867807070     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394387-3.00006-9     Document Type: Chapter

References (203)

1. Almenara J., Rosato R., Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002, 16:1331-1343.
2. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth & Differentiation 2000, 11:355-360.
3. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003, 102:652-658.
4. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews. Cancer 2002, 2:420-430.
5. Bachmann P.S., Piazza R.G., Janes M.E., Wong N.C., Davies C., Mogavero A., et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010, 116:3013-3022.
6. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research 2009, 15:5250-5257.
7. Bali P., George P., Cohen P., Tao J., Guo F., Sigua C., et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clinical Cancer Research 2004, 10:4991-4997.
8. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibiition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis of antileukemia activity of histone deacetylase inhibitors. The Journal of Biological Chemistry 2005, 280:26729-26734.
9. Bangert A., Cristofanon S., Eckhardt I., Abhari B.A., Kolodziej S., Hacker S., et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012, (in press).
10. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Letters 2009, 280:192-200.
11. Baumeister P., Dong D., Fu Y., Lee A.S. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Molecular Cancer Therapeutics 2009, 8:1086-1094. 2007.
12. Belinsky S.A., Grimes M.J., Picchi M.A., Mitchell H.D., Stidley C.A., Tesfaigzi Y., et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Research 2011, 71:454-462.
13. Belinsky S.A., Klinge D.M., Stidley C.A., Issa J.P., Herman J.G., March T.H., et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research 2003, 63:7089-7093.
14. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: Cell cycle regulators and beyond. Developmental Cell 2008, 14:159-169.
15. Bhalla S., Balasubramanian S., David K., Sirisawad M., Buggy J., Mauro L., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research 2009, 15:3354-3365.
16. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell 2008, 30:61-72.
17. Bhaskara S., Knutson S.K., Jiang G., Chandrasekharan M.B., Wilson A.J., Zheng S., et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010, 18:436-447.
18. Bubici C., Papa S., Pham C.G., Zazzeroni F., Franzoso G. NF-kappaB and JNK: An intricate affair. Cell Cycle 2004, 3:1524-1529.
19. Buglio D., Mamidipudi V., Khaskhely N.M., Brady H., Heise C., Besterman J., et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. British Journal of Haematology 2010, 151:387-396.
20. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 1999, 21:103-107.
21. Carew J.S., Nawrocki S.T., Kahue C.N., Zhang H., Yang C., Chung L., et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110:313-322.
22. Cerchietti L.C., Hatzi K., Caldas-Lopes E., Yang S.N., Figueroa M.E., Morin R.D., et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation 2010, 120(12):4569-4582.
23. Cha T.L., Chuang M.J., Wu S.T., Sun G.H., Chang S.Y., Yu D.S., et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clinical Cancer Research 2009, 15:840-850.
24. Chen S., Dai Y., Pei X.Y., Grant S. Bim up-regulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL and Mcl-1. Molecular and Cellular Biology 2009, 29:6149-6169.
25. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nature Reviews Molecular Cell Biology 2004, 5:392-401.
26. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. The EMBO Journal 2002, 21:6539-6548.
27. Chen H.Z., Tsai S.Y., Leone G. Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nature Reviews. Cancer 2009, 9:785-797.
28. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Molecular Cell 2004, 13:627-638.
29. Dai Y., Chen S., Kramer L.B., Funk V.L., Dent P., Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical Cancer Research 2008, 14:549-558.
30. Dai Y., Chen S., Venditti C.A., Pei X.Y., Nguyen T.K., Dent P., et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008, 112(3):793-804.
31. Dai Y., Chen S., Wang L., Pei X.Y., Kramer L.B., Dent P., et al. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbation in NF-kappaB and Bim. British Journal of Haematology 2011, 153(2):222-235.
32. Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., et al. The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology 2010, 151:70-83.
33. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-{kappa}B activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Molecular and Cellular Biology 2005, 25:5429-5444.
34. Daley G.Q. Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Seminars in Hematology 2003, 40:11-14.
35. Dasmahapatra G., Lembersky D., Kramer L., Fisher R.I., Friedberg J., Dent P., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115:4478-4487.
36. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P., Fisher R.I., et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics 2011, 10:1686-1697.
37. Dasmahapatra G., Yerram N., Dai Y., Dent P., Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clinical Cancer Research 2007, 13:4280-4290.
38. Davies C., Hogarth L.A., Dietrich P.A., Bachmann P.S., MacKenzie K.L., Hall A.G., et al. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. The Journal of Biological Chemistry 2011, 286:37639-37650.
39. Debatin K.M., Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23:2950-2966.
40. Denlinger C.E., Rundall B.K., Jones D.R. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. The Journal of Thoracic and Cardiovascular Surgery 2005, 130:1422-1429.
41. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21:427-436.
42. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
43. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology 2005, 45:495-528.
44. Erlich R.B., Kherrouche Z., Rickwood D., Endo-Munoz L., Cameron S., Dahler A., et al. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. British Journal of Cancer 2011, 106(1):107-115.
45. Ewings K.E., Hadfield-Moorhouse K., Wiggins C.M., Wickenden J.A., Balmanno K., Gilley R., et al. ERK1/2-dependent phosphorylation of Bim(EL) promotes its rapid dissociation from Mcl-1 and Bcl-x(L). The EMBO Journal 2007, 26:2856-2867.
46. Fan T., Jiang S., Chung N., Alikhan A., Ni C., Lee C.C., et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Molecular Cancer Research 2011, 9:418-429.
47. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Research 2008, 68:3785-3794.
48. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clinical Cancer Research 2006, 12:5869-5878.
49. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108:645-652.
50. Fiskus W., Wang Y., Joshi R., Rao R., Yang Y., Chen J., et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clinical Cancer Research 2008, 14:6106-6115.
51. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009, 15:57-66.
52. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics 2008, 7:759-768.
53. Gabrielli B., Chia K., Warrener R. Finally, how histone deacetylase inhibitors disrupt mitosis!. Cell Cycle 2011, 10:2658-2661.
54. Gammoh N., Lam D., Puente C., Ganley I., Marks P.A., Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:6561-6565.
55. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of Biological Chemistry 2002, 277:25748-25755.
56. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
57. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
58. Gaymes T.J., Padua R.A., Pla M., Orr S., Omidvar N., Chomienne C., et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?. Molecular Cancer Research 2006, 4:563-573.
59. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
60. Gillenwater A.M., Zhong M., Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Molecular Cancer Therapeutics 2007, 6:2967-2975.
61. Gillespie S., Borrow J., Zhang X.D., Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006, 11:2251-2265.
62. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
63. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
64. Golding S.E., Rosenberg E., Neill S., Dent P., Povirk L.F., Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Research 2007, 67:1046-1053.
65. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research 2006, 66:6361-6369.
66. Grant S., Easley C., Kirkpatrick P. Vorinostat. Nature Reviews. Drug Discovery 2007, 6:1-2.
67. Grant S., Kolla S., Sirulnik A., Shapiro G.I., Supko J.G., Cooper B., et al. Phase I trial of vorinostat (SAHA) in combination with alvocidib (flavopiridol) in patients with refractory, relapsed, or (selected) poor-prognosis AML or refractory anemia with excess blasts-2 (RAEB-2). Blood 2008, 112:2986. (Abstract).
68. Griffiths E.A., Gore S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in Hematology 2008, 45:23-30.
69. Gupta M., Ansell S.M., Novak A.J., Kumar S., Kaufmann S.H., Witzig T.E. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114:2926-2935.
70. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4389-4394.
71. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine 2012, 366:787-798.
72. Harrison S.J., Quach H., Link E., Seymour J.F., Ritchie D.S., Ruell S., et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011, 118:6274-6283.
73. Hewamana S., Lin T.T., Jenkins C., Burnett A.K., Jordan C.T., Fegan C., et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research 2008, 14:8102-8111.
74. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:8567-8572.
75. Hideshima T., Richardson P.G., Anderson K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Molecular Cancer Therapeutics 2011, 10:2034-2042.
76. Hu Y., Lu W., Chen G., Zhang H., Jia Y., Wei Y., et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 2010, 116:2732-2741.
77. Huang J.M., Sheard M.A., Ji L., Sposto R., Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Molecular Cancer Therapeutics 2010, 9:3289-3301.
78. Hug B.A., Lazar M.A. ETO interacting proteins. Oncogene 2004, 23:4270-4274.
79. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation 2004, 11(Suppl 2):S193-S206.
80. Inoue S., Riley J., Gant T.W., Dyer M.J., Cohen G.M. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007, 21:1773-1782.
81. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 2005, 11:71-76.
82. Ishii S., Kurasawa Y., Wong J., Yu-Lee L.Y. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4179-4184.
83. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
84. Jona A., Khaskhely N., Buglio D., Shafer J.A., Derenzini E., Bollard C.M., et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology 2011, 39:1007-1017.
85. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
86. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PloS One 2010, 5:e11208.
87. Kalac M., Scotto L., Marchi E., Amengual J., Seshan V.E., Bhagat G., et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011, 118:5506-5516.
88. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
89. Kauh J., Fan S., Xia M., Yue P., Yang L., Khuri F.R., et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PloS One 2010, 5:e10376.
90. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
91. Kilpivaara O., Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science. Leukemia 2008, 22:1813-1817.
92. Kim E.H., Kim H.S., Kim S.U., Noh E.J., Lee J.S., Choi K.S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005, 24:6877-6889.
93. Kim Y.K., Seo D.W., Kang D.W., Lee H.Y., Han J.W., Kim S.N. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochemical and Biophysical Research Communications 2006, 347:1088-1093.
94. Kirschbaum M., Frankel P., Popplewell L., Zain J., Delioukina M., Pullarkat V., et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology 2011, 29:1198-1203.
95. Koshikawa N., Hayashi J., Nakagawara A., Takenaga K. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. The Journal of Biological Chemistry 2009, 284:33185-33194.
96. Kretzner L., Scuto A., Dino P.M., Kowolik C.M., Wu J., Ventura P., et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Research 2011, 71:3912-3920.
97. LaBonte M.J., Wilson P.M., Fazzone W., Russell J., Louie S.G., El-Khoueiry A., et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Research 2011, 71:3635-3648.
98. Lammering G., Hewit T.H., Hawkins W.T., Contessa J.N., Reardon D.B., Lin P.S., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. Journal of the National Cancer Institute 2001, 93:921-929.
99. Lee J.H., Choy M.L., Ngo L., Foster S.S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(33):14639-14644.
100. Levine B., Klionsky D.J. Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Developmental Cell 2004, 6:463-477.
101. Li Y., Kao G.D., Garcia B.A., Shabanowitz J., Hunt D.F., Qin J., et al. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes & Development 2006, 20:2566-2579.
102. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8071-8076.
103. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. The Journal of Biological Chemistry 2003, 278:33714-33723.
104. Liu Y., Denlinger C.E., Rundall B.K., Smith P.W., Jones D.R. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. The Journal of Biological Chemistry 2006, 281:31359-31368.
105. Liu S., Liu Z., Xie Z., Pang J., Yu J., Lehmann E., et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008, 111:2364-2373.
106. MacCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Research 2005, 65:5399-5407.
107. Magnaghi-Jaulin L., Eot-Houllier G., Fulcrand G., Jaulin C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Research 2007, 67:6360-6367.
108. Marchion D.C., Bicaku E., Daud A.I., Richon V., Sullivan D.M., Munster P.N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Journal of Cellular Biochemistry 2004, 92:223-237.
109. Marks P.A., Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551.
110. Marks P.A., Richon V.M., Kelly W.K., Chiao J.H., Miller T. Histone deacetylase inhibitors: Development as cancer therapy. Novartis Foundation Symposium 2004, 259:269-281.
111. Martin B.P., Frew A.J., Bots M., Fox S., Long F., Takeda K., et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer 2011, 128:2735-2747.
112. Matsubara H., Watanabe M., Imai T., Yui Y., Mizushima Y., Hiraumi Y., et al. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone]. The Journal of Pharmacology and Experimental Therapeutics 2009, 328:839-848.
113. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
114. Miller C.P., Singh M.M., Rivera-Del V.N., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. Journal of Biomedicine and Biotechnology 2011, 2011:514261.
115. Miller K.M., Tjeertes J.V., Coates J., Legube G., Polo S.E., Britton S., et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nature Structural and Molecular Biology 2010, 17:1144-1151.
116. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:540-545.
117. Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British Journal of Cancer 2011, 104:1828-1835.
118. Nawrocki S.T., Carew J.S., Douglas L., Cleveland J.L., Humphreys R., Houghton J.A. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Research 2007, 67:6987-6994.
119. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner K., et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Research 2006, 66:3773-3781.
120. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner K., Huang P., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Research 2005, 65:11658-11666.
121. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine 2005, 11:77-84.
122. Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N., et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research 2011, 17:3219-3232.
123. Nguyen D.M., Schrump W.D., Chen G.A., Tsai W., Nguyen P., Trepel J.B., et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clinical Cancer Research 2004, 10:1813-1825.
124. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., Yokoyama A. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 2008, 22:1449-1452.
125. Nishioka C., Ikezoe T., Yang J., Takeuchi S., Koeffler H.P., Yokoyama A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leukemia Research 2008, 32:1382-1392.
126. Ocker M., Schneider-Stock R. Histone deacetylase inhibitors: Signalling towards p21cip1/waf1. The International Journal of Biochemistry & Cell Biology 2007, 39:1367-1374.
127. Okabe S., Tauchi T., Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Annals of Hematology 2010, 89:1081-1087.
128. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
129. O'reilly M.A. Redox activation of p21Cip1/WAF1/Sdi1: A multifunctional regulator of cell survival and death. Antioxidants & Redox Signaling 2005, 7:108-118.
130. Ott M., Norberg E., Zhivotovsky B., Orrenius S. Mitochondrial targeting of tBid/Bax: A role for the TOM complex?. Cell Death and Differentiation 2009, 16:1075-1082.
131. Ozaki K., Kosugi M., Baba N., Fujio K., Sakamoto T., Kimura S., et al. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochemical and Biophysical Research Communications 2010, 391:1610-1615.
132. Ozaki K., Minoda A., Kishikawa F., Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochemical and Biophysical Research Communications 2006, 339:1171-1177.
133. Park M.A., Mitchell C., Zhang G., Yacoub A., Allegood J., Haussinger D., et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Research 2010, 70:6313-6324.
134. Park M.A., Reinehr R., Haussinger D., Voelkel-Johnson C., Ogretmen B., Yacoub A., et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular Cancer Therapeutics 2010, 9:2220-2231.
135. Park M.A., Zhang G., Martin A.P., Hamed H., Mitchell C., Hylemon P.B., et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy 2008, 7:1648-1662.
136. Parry D., Guzi T., Shanahan F., Davis N., Prabhavalkar D., Wiswell D., et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Molecular Cancer Therapeutics 2010, 9:2344-2353.
137. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research 2004, 10:3839-3852.
138. Petruccelli L.A., Dupere-Richer D., Pettersson F., Retrouvey H., Skoulikas S., Miller W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PloS One 2011, 6:e20987.
139. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
140. Polo J.M., Dell'Oso T., Ranuncolo S.M., Cerchietti L., Beck D., Da Silva G.F., et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine 2004, 10:1329-1335.
141. Qian D.Z., Wang X., Kachhap S.K., Kato Y., Wei Y., Zhang L., et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research 2004, 64:6626-6634.
142. Rahmani M., Davis E.M., Crabtree T.R., Habibi J.R., Nguyen T.K., Dent P., et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Molecular and Cellular Biology 2007, 27:5499-5513.
143. Rahmani M., Reese E., Dai Y., Bauer C., Kramer L.B., Huang M., et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Molecular Pharmacology 2005, 67:1166-1176.
144. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research 2005, 65:2422-2432.
145. Rahmani M., Yu C., Reese E., Ahmed W., Hirsch K., Dent P., et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 2003, 22:6231-6242.
146. Rao R., Lee P., Fiskus W., Yang Y., Joshi R., Wang Y., et al. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: A highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biology & Therapy 2009, 8:1273-1280.
147. Rao R., Nalluri S., Fiskus W., Savoie A., Buckley K.M., Ha K., et al. Role of C/EBP homologous protein (CHOP) in Panobinostat-mediated potentiation of bortezomib-induced lethal ER stress in mantle cell lymphoma cells. Clinical Cancer Research 2010, 16(19):4742-4754.
148. Rascle A., Johnston J.A., Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Molecular and Cellular Biology 2003, 23:4162-4173.
149. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10014-10019.
150. Richter-Larrea J.A., Robles E.F., Fresquet V., Beltran E., Rullan A.J., Agirre X., et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010, 116:2531-2542.
151. Robbins A.R., Jablonski S.A., Yen T.J., Yoda K., Robey R., Bates S.E., et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005, 4:717-726.
152. Robert T., Vanoli F., Chiolo I., Shubassi G., Bernstein K.A., Rothstein R., et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011, 471:74-79.
153. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular Cancer Therapeutics 2003, 2:1273-1284.
154. Rosato R.R., Almenara J.A., Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research 2003, 63:3637-3645.
155. Rosato R.R., Almenara J.A., Kolla S.S., Maggio S.C., Coe S., Gimenez M.S., et al. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Molecular Cancer Therapeutics 2007, 6:692-702.
156. Rosato R.R., Almenara J.A., Maggio S.C., Coe S., Atadja P., Dent P., et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics 2008, 7:3285-3297.
157. Rosato R.R., Kolla S.S., Hock S.K., Almenara J.A., Patel A., Amin S., et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry 2010, 285:10064-10077.
158. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology 2006, 69:216-225.
159. Rottenberg S., Jaspers J.E., Kersbergen A., van der B.E., Nygren A.O., Zander S.A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17079-17084.
160. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10833-10838.
161. Saito Y., Suzuki H., Tsugawa H., Nakagawa I., Matsuzaki J., Kanai Y., et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009, 28:2738-2744.
162. Sampath D., Liu C., Vasan K., Sulda M., Puduvalli V.K., Wierda W.G., et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012, 119:1162-1172.
163. Santo L., Hideshima T., Kung A.L., Tseng J.C., Tamang D., Yang M., et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119:2579-2589.
164. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. The EMBO Journal 1998, 17:1675-1687.
165. Senderowicz A.M. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Investigational New Drugs 1999, 17:313-320.
166. Shao W., Growney J.D., Feng Y., O'Connor G., Pu M., Zhu W., et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. International Journal of Cancer 2010, 127:2199-2208.
167. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology 2006, 24:1770-1783.
168. Shubassi G., Robert T., Vanoli F., Minucci S., Foiani M. Acetylation: A novel link between double-strand break repair and autophagy. Cancer Research 2012, 72:1332-1335.
169. Smith K.T., Martin-Brown S.A., Florens L., Washburn M.P., Workman J.L. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chemistry & Biology 2010, 17:65-74.
170. Srivastava R.K., Kurzrock R., Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Molecular Cancer Therapeutics 2010, 9:3254-3266.
171. Stathis A., Hotte S.J., Chen E.X., Hirte H.W., Oza A.M., Moretto P., et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical Cancer Research 2011, 17:1582-1590.
172. Stevens F.E., Beamish H., Warrener R., Gabrielli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene 2008, 27:1345-1354.
173. Subramanian C., Opipari A.W., Bian X., Castle V.P., Kwok R.P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4842-4847.
174. Sung E.S., Kim A., Park J.S., Chung J., Kwon M.H., Kim Y.S. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010, 15:1256-1269.
175. Tan J., Zhuang L., Jiang X., Yang K.K., Karuturi K.M., Yu Q. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. The Journal of Biological Chemistry 2006, 281:10508-10515.
176. Tergaonkar V., Bottero V., Ikawa M., Li Q., Verma I.M. IkappaB kinase-independent IkappaBalpha degradation pathway: Functional NF-kappaB activity and implications for cancer therapy. Molecular and Cellular Biology 2003, 23:8070-8083.
177. Terui T., Murakami K., Takimoto R., Takahashi M., Takada K., Murakami T., et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Research 2003, 63:8948-8954.
178. Thurn K.T., Thomas S., Moore A., Munster P.N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology 2011, 7:263-283.
179. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:673-678.
180. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18:7016-7025.
181. Wang Y., Fiskus W., Chong D.G., Buckley K.M., Natarajan K., Rao R., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
182. Wang H., Zhou W., Zheng Z., Zhang P., Tu B., He Q., et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair 2012, 11:146-156.
183. Warrener R., Beamish H., Burgess A., Waterhouse N.J., Giles N., Fairlie D., et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. The FASEB Journal 2003, 17:1550-1552.
184. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clinical Cancer Research 2009, 15:5308-5316.
185. Whittaker S.J., Demierre M.F., Kim E.J., Rook A.H., Lerner A., Duvic M., et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology 2010, 28:4485-4491.
186. Wiegmans A.P., Alsop A.E., Bots M., Cluse L.A., Williams S.P., Banks K.M., et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Research 2011, 71:3603-3615.
187. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Research 2006, 66:944-950.
188. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Annals of the New York Academy of Sciences 2007, 1113:202-216.
189. Wozniak M.B., Villuendas R., Bischoff J.R., Aparicio C.B., Martinez Leal J.F., de La C.P., et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010, 95:613-621.
190. Xargay-Torrent S., Lopez-Guerra M., Saborit-Villarroya I., Rosich L., Campo E., Roue G., et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clinical Cancer Research 2011, 17:3956-3968.
191. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
192. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15540-15545.
193. Xu X., Xie C., Edwards H., Zhou H., Buck S.A., Ge Y. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PloS One 2011, 6:e17138.
194. Yang J., Kawai Y., Hanson R.W., Arinze I.J. Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. The Journal of Biological Chemistry 2001, 276:25742-25752.
195. Yi C., Ma M., Ran L., Zheng J., Tong J., Zhu J., et al. Function and molecular mechanism of acetylation in autophagy regulation. Science 2012, 336:474-477.
196. Yu C., Dasmahapatra G., Dent P., Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in Bcr/abl+ human leukemia cells. Leukemia 2005, 19:1579-1589.
197. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. Journal of the National Cancer Institute 2002, 94:504-513.
198. Yu C., Rahmani M., Almenara J., Subler M., Krystal G., Conrad D., et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Research 2003, 63:2118-2126.
199. Yu C., Rahmani M., Conrad D., Subler M., Dent P., Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003, 102:3765-3774.
200. Yu C., Rahmani M., Dent P., Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research 2004, 295:555-566.
201. Yu W., Wang J., Jin J., Qian W., Qian J., Cheng Y., et al. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leukemia Research 2011, 35:1212-1218.
202. Zeitlin B.D., Zeitlin I.J., Nor J.E. Expanding circle of inhibition: Small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. Journal of Clinical Oncology 2008, 26:4180-4188.
203. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:16090-16095.